Letrozole: A review of use in postmenopausal women with advanced breast cancer

Drugs

Volumn 56, Issue 6, 1998, Pages 1125-1140

  Lamb, H M ^a   Adkins, J C ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; ALDOSTERONE; AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CHOLESTEROL; ESTROGEN; HYDROCORTISONE; LETROZOLE; MEGESTROL; VOROZOLE;

ABDOMINAL PAIN; ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; ESTROGEN URINE LEVEL; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RASH; SOMNOLENCE; SURVIVAL TIME; VOMITING;

EID: 0032420836     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856060-00020     Document Type: Article

References (54)

1. 1. WR Miller P Mullen P Sourdaine 1997 Regulation of aroma-tase activity within the breast J Steroid Biochem Mol Biol 61 193 202 9365190 Miller WR, Mullen P, Sourdaine P, et al. Regulation of aroma-tase activity within the breast. J Steroid Biochem Mol Biol 1997 Apr; 61: 193–202
2. 2. RJ Santen 1993 Estrogen synthesis inhibitors: from “off the rack” to haute couture [editorial; comment] J Clin Endocrinol Metab 77 316 8 8345033 10.1210/jc.77.2.316 1:STN:280:DyaK3szks1Ggug%3D%3D Santen RJ. Estrogen synthesis inhibitors: from “off the rack” to haute couture [editorial; comment]. J Clin Endocrinol Metab 1993 Aug; 77: 316–8
3. 3. S Masamura H Adlercreutz H Harvey 1995 Aromatase inhibitor development for treatment of breast cancer Breast Cancer Res Treat 33 19 26 7749129 10.1007/BF00666067 1:STN:280:DyaK2M3mvVSkug%3D%3D Masamura S, Adlercreutz H, Harvey H, et al. Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 1995 Jan; 33: 19–26
4. 4. PE Lønning M Dowsett TJ Powles 1990 Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer J Steroid Biochem Mol Biol 35 3/4 355 66 Lønning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem Mol Biol 1990; 35(3/4): 355–66
5. 5. M Dowsett A Jones SRD Johnston 1995 In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer Clin Cancer Res 1 1511 5 9815951 1:CAS:528:DyaK28XmvVWitQ%3D%3D Dowsett M, Jones A, Johnston SRD, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995 Dec; 1: 1511–5
6. 6. M Dowsett A Mehta N King 1992 An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients Eur J Cancer 28 2/3 415 20 1591054 10.1016/S0959-8049(05)80065-6 1:CAS:528:DyaK38XksVSksrg%3D Dowsett M, Mehta A, King N, et al. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer 1992; 28(2/3): 415–20
7. 7. PE Lønning S-I Helle DC Johannessen 1995 Relation between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients Clin Endocrinol 42 23 30 10.1111/j.1365-2265.1995.tb02594.x Lønning PE, Helle S-I, Johannessen DC, et al. Relation between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol 1995; 42: 23–30
8. 8. AS Bhatnagar C Batzl A Häusler 1996 Pharmacology of non-steroidal aromatase inhibitors JR Pasqualini BS Katzenellenbogen Hormone-dependent cancer Marcel Dekker, Inc New York 155 68 Bhatnagar AS, Batzl C, Häusler A, et al. Pharmacology of non-steroidal aromatase inhibitors. In: Pasqualini JR, Katzenellenbogen BS, editors. Hormone-dependent cancer. New York: Marcel Dekker, Inc., 1996: 155–68
9. 9. Y-C Kao LL Cam CA Laughton 1996 Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study Cancer Res 56 3451 60 8758911 1:CAS:528:DyaK28Xks1els7c%3D Kao Y-C, Cam LL, Laughton CA, et al. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 1996 Aug 1; 56: 3451–60
10. 10. M Kudoh Y Susaki Y Ideyama 1995 The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511 J Steroid Biochem Mol Biol 54 265 71 7577709 10.1016/0960-0760(95)00136-N 1:CAS:528:DyaK2MXptVWltr4%3D Kudoh M, Susaki Y, Ideyama Y, et al. The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. J Steroid Biochem Mol Biol 1995 Sep; 54: 265–71
11. 11. PE Lønning 1996 Pharmacology of new aromatase inhibitors Breast 5 3 202 8 10.1016/S0960-9776(96)90094-6 Lønning PE. Pharmacology of new aromatase inhibitors. Breast 1996; 5(3): 202–8
12. 12. TJ Iveson IE Smith J Ahern 1993 Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women J Clin Endocrinol Metab 77 324 31 8345035 10.1210/jc.77.2.324 1:CAS:528:DyaK3sXmtFKrurs%3D Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993 Aug; 77: 324–31
13. 13. LM Deniers 1994 Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients Breast Cancer Res Treat 30 1 95 102 10.1007/BF00682744 Deniers LM. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994; 30(1): 95–102
14. 14. A Lipton LM Deniers HA Harvey 1995 Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer Cancer 75 2132 8 7697604 10.1002/1097-0142(19950415)75:8<2132::AID-CNCR2820750816>3.0.CO;2-U 1:STN:280:DyaK2M3htFOitA%3D%3D Lipton A, Deniers LM, Harvey HA, et al. Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995 Apr 15; 75: 2132–8
15. 15. KO Klein LM Deniers SJ Santner 1995 Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole J Clin Endocrinol Metab 80 2658 60 7673408 10.1210/jc.80.9.2658 1:CAS:528:DyaK2MXotFyit7s%3D Klein KO, Deniers LM, Santner SJ, et al. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 1995 Sep; 80: 2658–60
16. 16. PE Lønning 1996 Aromatase inhibition for breast cancer treatment Acta Oncol 35 5 38 43 9142963 10.3109/02841869609083966 Lønning PE. Aromatase inhibition for breast cancer treatment. Acta Oncol 1996; 35(5) Suppl.: 38–43
17. 17. E Bajetta N Zilembo L Guillevin 1998 Endocrine trial comparing 0.5 and 2.5 mg of letrozole in postmenopausal patients (pts) with advanced breast cancer (ABC) [abstract no. 879] Proc Am Soc Clin Oncol 17 229a Bajetta E, Zilembo N, Guillevin L, et al. Endocrine trial comparing 0.5 and 2.5 mg of letrozole in postmenopausal patients (pts) with advanced breast cancer (ABC) [abstract no. 879]. Proc Am Soc Clin Oncol 1998; 17: 229a
18. 18. TJ Iveson IE Smith J Ahern 1993 Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer Cancer Res 53 266 70 8417819 1:STN:280:DyaK3s7htlGrtg%3D%3D Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993 Jan 15; 53: 266–70
19. 19. G Bisagni G Cocconi F Scaglione 1996 Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer Apilot study. Ann Oncol 7 99 102 10.1093/oxfordjournals.annonc.a010490 1:STN:280:DyaK2s%2FnslSjtQ%3D%3D Bisagni G, Cocconi G, Scaglione F, et al. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. Apilot study. Ann Oncol 1996 Jan; 7: 99–102
20. 20. G-M Castiglione 1996 New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity Eur J Can 32A 3 393 5 10.1016/0959-8049(95)00013-5 Castiglione Gertsch-M. New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity. Eur J Can 1996; 32A(3): 393–5
21. 21. S Masamura SJ Santner P Gimotty 1997 Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake Breast Cancer Res Treat 42 215 26 9065605 10.1023/A:1005714312092 1:CAS:528:DyaK2sXitlakur4%3D Masamura S, Santner SJ, Gimotty P, et al. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Res Treat 1997; 42: 215–26
22. 22. A Lipton SJ Santner RJ Santen 1987 Aromatase activity in primary and metastatic human breast cancer Cancer 59 779 82 3802035 10.1002/1097-0142(19870215)59:4<779::AID-CNCR2820590419>3.0.CO;2-U 1:STN:280:DyaL2s7gt1Gjug%3D%3D Lipton A, Santner SJ, Santen RJ, et al. Aromatase activity in primary and metastatic human breast cancer. Cancer 1987; 59: 779–82
23. 23. WR Miller J O’Neill 1987 The importance of local synthesis of estrogen within the breast Steroids 50 4-6 537 48 3504615 10.1016/0039-128X(87)90037-7 1:STN:280:DyaL1M%2Fntlaitw%3D%3D Miller WR, O’Neill J. The importance of local synthesis of estrogen within the breast. Steroids 1987; 50(4-6): 537–48
24. 24. M Dowsett K Lee VM Macaulay 1996 The control and biological importance of intratumoural aromatase in breast cancer J Steroid Biochem Mol Biol 56 145 50 8603035 10.1016/0960-0760(95)00231-6 1:CAS:528:DyaK28XitVeqtL4%3D Dowsett M, Lee K, Macaulay VM, et al. The control and biological importance of intratumoural aromatase in breast cancer. J Steroid Biochem Mol Biol 1996 Jan; 56 (1-6 Spec Nos): 145–50
25. 25. WR Miller J Telford C Love 1997 Qualitative effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast [abstract] Breast 6 228 10.1016/S0960-9776(97)90593-2 Miller WR, Telford J, Love C, et al. Qualitative effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast [abstract]. Breast 1997 Aug; 6: 228
26. 26. K Lee VM Macaulay JE Nicholls 1995 An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells Int J Cancer 62 297 302 7628871 10.1002/ijc.2910620311 1:CAS:528:DyaK2MXnsFGnsb4%3D Lee K, Macaulay VM, Nicholls JE, et al. An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells. Int J Cancer 1995 Jul 28; 62: 297–302
27. 27. W Yue J Wang A Savinov 1995 Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model Cancer Res 55 3073 7 7606729 1:CAS:528:DyaK2MXmvVyit7o%3D Yue W, Wang J, Savinov A, et al. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 1995 Jul 15; 55: 3073–7
28. 28. A Brodie Q Lu Y Liu 1998 Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer Oncology 123 5 36 40 Brodie A, Lu Q, Liu Y, et al. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology 1998 Mar; 12 (3) Suppl. 5: 36–40
29. 29. Lu Q, Liu Y, Long B, et al. Combined treatment with aromatase inhibitors and tamoxifen in a nude mice model [abstract no. 2616]. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research 1998: Mar 28–Apr 1; New Orleans (LA); 39: 384-5
30. 30. K Schieweck AS Bhatnagar C Batzl 1993 Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors J Steroid Biochem Mol Biol 44 633 6 8476774 10.1016/0960-0760(93)90270-7 1:CAS:528:DyaK3sXksVSnsb8%3D Schieweck K, Bhatnagar AS, Batzl C, et al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993 Mar; 44: 633–6
31. 31. HM Heshmati S Khosla SP Robins 1997 Endogenous residual estrogen levels determine bone resorption even in late postmenopausal women [abstract no. 76] J Bone Miner Res 12 1 121 Heshmati HM, Khosla S, Robins SP, et al. Endogenous residual estrogen levels determine bone resorption even in late postmenopausal women [abstract no. 76]. J Bone Miner Res 1997; 12 Suppl. 1: 121
32. 32. A Sioufi N Gauducheau V Pineau 1997 Absolute bioavailability of letrozole in healthy postmenopausal women Biopharm Drug Dispos 18 779 89 9429742 10.1002/(SICI)1099-081X(199712)18:9<779::AID-BDD64>3.0.CO;2-5 1:CAS:528:DyaK1cXmslSi Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 1997 Dec; 18: 779–89
33. 33. A Sioufi N Sandrenan J Godbillon 1997 Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration Biopharm Drug Dispos 18 489 97 9267682 10.1002/(SICI)1099-081X(199708)18:6<489::AID-BDD36>3.0.CO;2-P 1:CAS:528:DyaK2sXlsFeitrs%3D Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Biopharm Drug Dispos 1997 Aug; 18: 489–97
34. 34. Novartis Pharmaceuticals Corporation. Femara™ (letrozole tablets) prescribing information. East Hanover, NJ, USA, 1997
35. 35. B Wirz B Valles A Parkinson 1996 CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (Rm Femara) [abstract] 7th ISSX 10 359 Wirz B, Valles B, Parkinson A, et al. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (Rm Femara) [abstract]. 7th ISSX 1996 Oct 20; 10: 359
36. 36. JM Morgan M Palmisano S Spencer 1996 Pharmacokinetic effect of cimetidine on a single 2.5 mg dose of letrozole in healthy subjects [abstract] J Clin Pharmacol 36 852 Morgan JM, Palmisano M, Spencer S, et al. Pharmacokinetic effect of cimetidine on a single 2.5 mg dose of letrozole in healthy subjects [abstract]. J Clin Pharmacol 1996 Sep; 36: 852
37. 37. M Dowsett CU Pfister SRD Johnston 1997 Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer [abstract] Breast 6 245 Dowsett M, Pfister CU, Johnston SRD, et al. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer [abstract]. Breast 1997 Aug; 6: 245
38. 38. N Zilembo A Leo Di E Bajetta 1996 Two different letrozole doses in the treatment of postmenopausal advanced breast cancer [abstract no. 105] Proc Am Soc Clin Oncol 15 110 Zilembo N, Di Leo A, Bajetta E, et al. Two different letrozole doses in the treatment of postmenopausal advanced breast cancer [abstract no. 105]. Proc Am Soc Clin Oncol 1996 Mar 15: 110
39. 39. JN Ingle PA Johnson VJ Suman 1997 A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma Cancer 80 218 24 9217033 10.1002/(SICI)1097-0142(19970715)80:2<218::AID-CNCR8>3.0.CO;2-P 1:CAS:528:DyaK2sXkvFCgtr0%3D Ingle JN, Johnson PA, Suman VJ, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997 Jul 15; 80: 218–24
40. 40. T Tominaga Y Ohashi R Abe 1998 Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer [abstract] Eur J Cancer 31A 5 S81 Tominaga T, Ohashi Y, Abe R, et al. Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer [abstract]. Eur J Cancer 1998 (31A) Suppl. 5: S81
41. 41. P Dombernowsky I Smith G Falkson 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol 16 453 61 9469328 1:CAS:528:DyaK1cXhtFSht7c%3D Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998 Feb; 16: 453–61
42. 42. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998 (9): 639-45
43. 43. IE Smith 1998 Pivotal trials of letrozole: a new aromatase inhibitor Oncology 125 5 41 4 Smith IE. Pivotal trials of letrozole: a new aromatase inhibitor. Oncology 1998 Mar; 12 (5) Suppl. 5: 41–4
44. 44. M Gershanovich HA Chaudri U Hornberger 1998 Comparison of letrozole 2.5mg (Femara R) with megestrol acetate (MA) and with aminoglutethimide (AG) in patients with visceral disease [abstract no. 212] Breast Cancer Res Treat 46 53 Gershanovich M, Chaudri HA, Hornberger U, et al. Comparison of letrozole 2.5mg (Femara R) with megestrol acetate (MA) and with aminoglutethimide (AG) in patients with visceral disease [abstract no. 212]. Breast Cancer Res Treat 1998; 46: 53
45. 45. KP Weinfurt SL Wait W Boyko 1998 Psychosocial quality of life in a phase III trial of letrozole [abstract no. 417] Proc Am Soc Clin Oncol 17 108a Weinfurt KP, Wait SL, Boyko W, et al. Psychosocial quality of life in a phase III trial of letrozole [abstract no. 417]. Proc Am Soc Clin Oncol 1998; 17: 108a
46. 46. JM Dixon CDB Love S Tucker 1997 Letrozole as primary medical therapy for locally advanced breast cancer [abstract] Breast 6 245 6 10.1016/S0960-9776(97)90656-1 Dixon JM, Love CDB, Tucker S, et al. Letrozole as primary medical therapy for locally advanced breast cancer [abstract]. Breast 1997 Aug; 6: 245–6
47. 47. JM Dixon CDB Love S Tucker 1998 Letrozole as primary medical therapy for locally advanced and large operable breast cancer [abstract no. 400] Proc Am Soc Clin Oncol 17 104a Dixon JM, Love CDB, Tucker S, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer [abstract no. 400]. Proc Am Soc Clin Oncol 1998; 17: 104a
48. 48. A Goldhirsch RD Gelber 1996 Endocrine therapies of breast cancer Semin Oncol 23 4 494 505 8757275 1:CAS:528:DyaK28XlslyltrY%3D Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 1996; 23(4): 494–505
49. 49. British National Formulary. No. 35: The Pharmaceutical Press, 1998, Mar
50. 50. TG Hayes LE Peterson AD Weinberg 1998 Current guidelines for the diagnosis and treatment of breast cancer Dis Manage Health Outcomes 3 5 239 50 10.2165/00115677-199803050-00004 Hayes TG, Peterson LE, Weinberg AD. Current guidelines for the diagnosis and treatment of breast cancer. Dis Manage Health Outcomes 1998 May; 3(5): 239–50
51. 51. M Dowsett 1997 Future uses for aromatase inhibitors in breast cancer J Steroid Biochem Mol Biol 61 3-6 261 6 9365199 10.1016/S0960-0760(97)80021-0 1:CAS:528:DyaK2sXnt1CrtLg%3D Dowsett M. Future uses for aromatase inhibitors in breast cancer. J Steroid Biochem Mol Biol 1997; 61(3-6): 261–6
52. 52. A Howell S Downey E Anderson 1996 New endocrine therapies for breast cancer Eur J Can 32A 576 88 10.1016/0959-8049(96)00032-9 1:STN:280:DyaK283ntlGhuw%3D%3D Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur J Can 1996 Apr; 32A: 576–88
53. 53. LR Wiseman CM Spencer 1997 Vorozole Drugs Aging 11 245 50 9303282 10.2165/00002512-199711030-00007 1:CAS:528:DyaK2sXmt1Ortbo%3D Wiseman LR, Spencer CM. Vorozole. Drugs Aging 1997 Sep; 11: 245–50
54. 54. LR Wiseman JC Adkins 1998 Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer Drugs Aging 13 4 321 32 9805213 10.2165/00002512-199813040-00008 1:CAS:528:DyaK1cXntlSqsr8%3D Wiseman LR, Adkins JC. Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998 Oct; 13(4): 321–32